Summary
Gidazepam is an atypical benzodiazepine developed in the Soviet Union, licensed for use in Russia and Ukraine under the brand name Gidazepam IC. It functions as a prodrug metabolized to desalkylgidazepam (bromo-nordazepam). Unlike typical benzodiazepines, gidazepam has minimal sedative and hypnotic effects, making it suitable for daytime use. It has a uniquely delayed onset (30-60 minutes) and exceptionally long half-life (86-87 hours). Therapeutic doses range from 60-200 mg daily, divided into 2-3 doses.
Dose Information
Light
Common
Strong
Heavy
Onset, Duration & After-effects
| ROA | Onset | Comeup | Peak | Offset |
|---|---|---|---|---|
| Oral | 30-60 min | 1-2 hrs | 1-4 hrs | 6-12 hrs |
Tolerance
Build-up
develops over 1–4 weeks of daily use; hypnotic tolerance faster than anxiolytic tolerance
Reset
weeks to months depending on half-life and duration of use; taper recommended
Effects
Positive
- Muscle relaxation
- Physical euphoria
- Stimulation
- Anxiolytic
- Muscle Relaxant
Negative
- Motor impairment
- Respiratory depression
- Sedation
- Sedative
- Dystaxia
Positive
- Anxiety suppression
- Cognitive clarity
- Reduced anxiety
Negative
- Emotion suppression
- Motor control loss
- Amnesia
- Dizziness
- Thought deceleration
- Compulsive redosing
- Delusions of sobriety
Positive
- Increased libido
- Appetite enhancement
Negative
- Disinhibition
- Acuity suppression
- Visual acuity suppression
- Decreased Libido
- Acuity Suppression
- Double vision
- Dulled perception
- Perception of bodily heaviness